NCT02467153 (EXVITD) is a NA clinical trial of RET in Sarcopenia, sponsored by University of Birmingham.

Who is sponsoring NCT02467153?

NCT02467153 is sponsored by University of Birmingham.

What drugs are being tested in NCT02467153?

Interventions in NCT02467153: RET, Placebo, Vitamin D3.

What condition does NCT02467153 study?

NCT02467153 studies Sarcopenia, Muscle Atrophy, Osteoporosis.

Is NCT02467153 still recruiting?

NCT02467153 is currently completed. Last updated 10 February 2022.

Last reviewed 2022-02-10 · How we verify

NCT02467153: EXVITD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vitamin D and Resistance Exercise Training; Effects on Musculoskeletal Health in Frail Older Men and Women

Completed NA Last updated 10 February 2022

What this trial tests

NA trial testing RET in Sarcopenia in 19 participants. Completed in 16 December 2019.

Timeline

1 January 2017

Primary endpoint
31 October 2019

16 December 2019

Quick facts

Lead sponsor	University of Birmingham
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	19
Start date	1 January 2017
Primary completion	31 October 2019
Estimated completion	16 December 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

RET
Placebo
Vitamin D3 (cholecalciferol) — full drug profile →

Conditions studied

Sarcopenia — all drugs for Sarcopenia →
Muscle Atrophy — all drugs for Muscle Atrophy →
Osteoporosis — all drugs for Osteoporosis →

Sponsor

University of Birmingham

Who can join

65 and older, any sex, with Sarcopenia or Muscle Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to determine whether vitamin D3 supplementation is any more effective in improving musculoskeletal function when combined with exercise training compared with exercise training alone.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life.
Rutjes AW, Denton DA, Di Nisio M, Chong LY, et al · · 2018 · cited 96× · PMID 30556597 · DOI 10.1002/14651858.cd011906.pub2
Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment.
McCleery J, Abraham RP, Denton DA, Rutjes AW, et al · · 2018 · cited 95× · PMID 30383288 · DOI 10.1002/14651858.cd011905.pub2
Sarcopenia and Muscle Aging: Updated Insights into Molecular Mechanisms and Translational Therapeutics.
Nguyen TT, Dao T, Nguyen HT, Park JH, et al · · 2026 · cited 1× · PMID 41674227 · DOI 10.3803/enm.2025.2656
Influence of combined vitamin D<sub>3</sub> supplementation and resistance exercise training on musculoskeletal health in older men and women (EXVITD): protocol for a randomised controlled trial.
Welford AE, Lanham-New S, Lord J, Doyle A, et al · · 2020 · cited 1× · PMID 32193264 · DOI 10.1136/bmjopen-2019-033824

Verify or expand the search:

Other recruiting trials for Sarcopenia

Currently open trials in the same condition.

NCT07500376 — Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery · recruiting
NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia · NA · active not recruiting
NCT07426159 — AI-Guided Sarcopenia Risk Assessment and Detection · NA · active not recruiting

Other University of Birmingham trials

Trials by the same sponsor.

NCT07160686 — Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment · Phase 3 · not yet recruiting
NCT07446166 — TETANUS Antibody Detection in Saliva Study · NA · not yet recruiting
NCT07294794 — Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension · NA · not yet recruiting
NCT07246356 — Feasibility and Efficacy of GTEP for Birth Trauma · NA · recruiting
NCT06932653 — Reducing Deaths After Surgery in Low- and Middle-income Countries: A Pilot Cluster Randomised Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02467153 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Birmingham
Last refreshed: 10 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02467153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing